ArticleFrontiers in oncology2025
A gelatin sponge-hemocoagulase sealant for preventing tumor biopsy complications: a dual mechanical and pharmacological barrier.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: CT-guided biopsy of a mediastinal mass in the visceral compartment.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A CT-guided tumor biopsies carry substantial risks, with literature-reported complication rates reaching 43% and pulmonary biopsy pneumothorax intervention rates as high as 22.1%. This study validates a novel needle tract sealing technique combining absorbable gelatin sponge (mechanical occlusion) with Agkistrodon acutus-derived hemocoagulase (local coagulation), leveraging synergistic physico-chemical mechanisms. Methods: This prospective single-arm cohort enrolled 87 consecutive patients undergoing CT-guided biopsies (Feb 2023-Jun 2025). The core technique involved retrograde injection during needle withdrawal of 1mm³ gelatin sponge particles suspended in 0.5KU hemocoagulase (total volume: 1.5ml), with stratified dosing for D-dimer levels >2mg/L. Primary outcomes were intervention-requiring complications such as symptomatic pneumothorax or clinically significant hemorrhage. Results: Among 87 patients (42 pulmonary), the composite technique reduced overall complications to 4.6% (4/87) vs 43% literature rate ( Conclusion: The gelatin sponge-hemocoagulase composite significantly reduces CT-guided biopsy complications through dual mechanical-coagulation mechanisms, establishing a universally applicable, precision-stratified safety protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.